Clinical Trial Update: Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major [NA]

View source ↗

Summary

This completed clinical trial evaluated the feasibility and safety of mobilizing CD34+ hematopoietic progenitor cells using granulocyte colony-stimulating facto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Congenital Anemia

Drugs mentioned

• Neupogen (Filgrastim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Beta Thalassemia Major, Congenital Anemias | NA | Status: COMPLETED | Results posted: 2016-11-25